The Medipattern Corporation

The Medipattern Corporation

October 22, 2009 06:30 ET

Medipattern Takes B-CAD-FOR-LIFE™ Program to National Scale in the United States

TORONTO, ONTARIO--(Marketwire - Oct. 22, 2009) - The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, will be introducing its B-CAD-FOR-LIFE™ program at RSNA 2009. Medipattern's B-CAD® computer-aided detection (CAD) helps physicians to assess breast lesions increasing accuracy through standardizing reporting and the use of the American College of Radiology BI-RADS® (Breast Imaging-Reporting and Data System) lexicon. The new B-CAD-FOR-LIFE program provides all of the separate components that are required to install, train, use and maintain B-CAD under one monthly service fee. Medipattern has installed over one hundred B-CAD software licenses using the B-CAD-FOR-LIFE program at key practices including Long Island Radiology Associates, Manhattan Diagnostic Radiology, Metropolitan Diagnostic Imaging, XXI Century Radiology Imaging and Zwanger-Pesiri, with widely acclaimed response to the program. It is estimated that physicians are interpreting the images from over 4,000 patients per month with B-CAD through this program based upon average daily usage volume, once installation and training have been completed in all the facilities that have signed up for this program to date.

"We are a small business on a tight budget," stated Olga Tsireshkin, MD founder of XXI Century Radiology and Imaging, P. C. located in Brooklyn, New York. "With B-CAD-FOR-LIFE, Medipattern installs B-CAD, trains our staff in how to use it and maintains it for a monthly fee. This can give XXI Century immediate access to all of the benefits of B-CAD: saving time in documenting each case, improving communication of detailed information, and that CAD second opinion in an affordable package."

"MDR offers state-of-the-art diagnostic imaging and B-CAD® enhances our use of ultrasound and our ability to report and communicate findings," comments Craig Sherman, MD, Senior Partner Manhattan Diagnostic Radiology. 

"We are impressed with B-CAD's clinical value. B-CAD creates a concise synopsis of the case with a breast map showing the location and description," commented Linda Bolger, Director of Managed Care. 

"B-CAD will enable us to have comprehensive standardized breast ultrasound reports that conform to the American College of Radiology (ACR) BI-RADS® ultrasound lexicon. We have learned that the use of standardized protocols increases throughput while maintaining a high standard of medical excellence," concluded Steven Mendelsohn, MD medical director and co-owner of Zwanger-Pesiri Radiology.

"B-CAD has been proven to increase diagnostic accuracy by 44 percent in lesions less than 1 CM in a paper by Dr. Jun Lai Li and Dr. Dan Fei Song, and published in the American Journal of Clinical Oncology. We wanted to provide our customers an affordable solution enabling access to the latest ultrasound B-CAD innovations. We piloted the program in the New York area where it has been well received," added Jeff Collins, CEO of The Medipattern Corporation. "B-CAD-FOR-LIFE is ready to roll out in the U.S. on a National scale."

2009 Upcoming Events:

  • Visit Medipattern at booth 1009 at RSNA (Radiological Society of North America), November 29 to December 3, 2009, Chicago, IL.

About The Medipattern Corporation:
® (TSX VENTURE:MKI) is a pioneer in the development of medical software solutions that help improve imaging workflow and productivity. Our first-to-market, award-winning B-CAD® advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its Cadenza™ CAD Technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective. For more information, please visit the Company's website at:

B-CAD® and Medipattern® are a registered mark of The Medipattern Corporation.

Forward-looking statements
This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates,'' "believes,'' "estimates,'' "expects,'' "plans,'' "intends,'' "potential'', and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information